These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34997873)

  • 1. Activation of C3 and C5 May Be Involved in the Inflammatory Progression of PCM and GM.
    Li XQ; Sun HG; Wang XH; Zhang HJ; Zhang XS; Yu Y; Liu J; Guo QQ; Yang ZL
    Inflammation; 2022 Apr; 45(2):739-752. PubMed ID: 34997873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAC mediates mammary duct epithelial cell injury in plasma cell mastitis and granulomatous mastitis.
    Zhang HJ; Ding PP; Zhang XS; Wang XC; Sun DW; Bu QA; Li XQ
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109303. PubMed ID: 36252469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Anaphylatoxin Receptor Expression and C3a/C5a Functions in Anaphylatoxin Receptor Reporter Mice.
    Laumonnier Y; Karsten CM; Köhl G; Köhl J
    Curr Protoc Immunol; 2020 Sep; 130(1):e100. PubMed ID: 32710701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3aR and C5aR1 act as key regulators of human and mouse β-cell function.
    Atanes P; Ruz-Maldonado I; Pingitore A; Hawkes R; Liu B; Zhao M; Huang GC; Persaud SJ; Amisten S
    Cell Mol Life Sci; 2018 Feb; 75(4):715-726. PubMed ID: 28921001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4
    Hansen CB; Willer A; Bayarri-Olmos R; Kemper C; Garred P
    Immunobiology; 2019 Mar; 224(2):307-315. PubMed ID: 30612786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The complement C3a and C5a signaling in renal diseases: a bridge between acute and chronic inflammation.
    Buelli S; Imberti B; Morigi M
    Nephron; 2024 Mar; ():. PubMed ID: 38452744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation in type 1 human diabetes.
    Sundsmo JS; Papin RA; Wood L; Hirani S; Waldeck N; Buckingham B; Kershnar A; Ascher M; Charles MA
    Clin Immunol Immunopathol; 1985 May; 35(2):211-25. PubMed ID: 3907907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells.
    Shivshankar P; Li YD; Mueller-Ortiz SL; Wetsel RA
    FASEB J; 2020 Jun; 34(6):7540-7560. PubMed ID: 32301538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal Injury Activates Complement Expression in Müller Cells Leading to Neuroinflammation and Photoreceptor Cell Death.
    Tabor SJ; Yuda K; Deck J; Gnanaguru G; Connor KM
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy.
    Liu L; Zhang Y; Duan X; Peng Q; Liu Q; Zhou Y; Quan S; Xing G
    J Clin Immunol; 2014 Feb; 34(2):224-32. PubMed ID: 24327134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Activation of complement and serial changes of anaphylatoxin (C3a, C5a) in patients for open-heart surgery using a membrane oxygenator].
    Mitsuhata H; Enzan K; Hasegawa J; Matumoto S; Matsumoto J; Kurosawa S
    Masui; 1992 Feb; 41(2):194-9. PubMed ID: 1552659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts on the therapeutic control of complement anaphylatoxin receptors.
    Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
    Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions.
    Purwar R; Wittmann M; Zwirner J; Oppermann M; Kracht M; Dittrich-Breiholz O; Gutzmer R; Werfel T
    J Immunol; 2006 Oct; 177(7):4444-50. PubMed ID: 16982879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.
    Li XX; Kumar V; Clark RJ; Lee JD; Woodruff TM
    Front Pharmacol; 2020; 11():591398. PubMed ID: 33551801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma.
    Engelke C; Wiese AV; Schmudde I; Ender F; Ströver HA; Vollbrandt T; König P; Laumonnier Y; Köhl J
    J Immunol; 2014 Dec; 193(11):5387-401. PubMed ID: 25355927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of complement fragment C5a in milk is variable among cows.
    Rainard P; Poutrel B
    J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.
    Zhang Y; Yan X; Zhao T; Xu Q; Peng Q; Hu R; Quan S; Zhou Y; Xing G
    Clin Exp Immunol; 2017 Jul; 189(1):60-70. PubMed ID: 28295247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocyte aggregation response to quantitative plasma levels of C3a and C5a.
    Williams JJ; Yellin SA; Slotman GJ
    Arch Surg; 1986 Mar; 121(3):305-7. PubMed ID: 3484946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
    Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
    Front Immunol; 2018; 9():1691. PubMed ID: 30083158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.